



CytoSorb Therapy

Decision support in cardiac surgery use

- Postoperative
- Intraoperative





This chart is based on clinical data and best practice gained with CytoSorb 300 and not transferable to any other blood purification device.

Intraoperative Initiation

The intraoperative use of CytoSorb Therapy should be considered if one or more of the following aspects is given:

Goal: Reduce risk of systemic hyperinflammation

- ▶ Complex intervention with expected long CPB time (> 120 min) ?
 - Combination procedure
 - Redo procedure
- ▶ Acute, infective endocarditis requiring valve replacement ?
- ▶ Heart transplant surgery ?
- ▶ Aortic dissection ?
- ▶ High patient comorbidity and/or pre-existing liver/renal dysfunction ?
- ▶ Increased risk for the development of intra- & postoperative, hyperinflammatory based complications ?

Goal: Reduce risk of bleeding complications

- ▶ Urgent or emergent cardiac surgery in patients treated with ticagrelor and/or rivaroxaban ?

CytoSorbents Europe GmbH

Müggelseedamm 131
12587 Berlin | Germany

T +49 30 65 49 91 45
F +49 30 65 49 91 46
support@cytosorbents.com

follow us on

This decision guidance is non-binding and cannot replace the therapy decisions of the treating physician, who is in all cases responsible for the development and implementation of an adequate diagnostic and therapeutic plan for each individual patient.

The clinical and preclinical data and results obtained with the CytoSorb adsorber are not transferable to other products. CytoSorb should only be administered by personnel who have been properly trained in administration of extracorporeal therapies. CytoSorb is not available for commercial sale in USA. CytoSorb and CytoSorbents are trademarks of the CytoSorbents Corporation, USA. © Copyright 2020, CytoSorbents Europe GmbH. All rights reserved. B1082R03ENG2020